Tags

Type your tag names separated by a space and hit enter

Sertraline for the treatment of depression in Parkinson's disease.
Mov Disord. 1997 Sep; 12(5):756-9.MD

Abstract

Although antidepressant medications are commonly used to treat depression in Parkinson's disease (PD), little information is available regarding their safety and efficacy in this condition. Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inhibitor activity. It has a favorable tolerability profile, especially in the elderly. We undertook an open-label pilot evaluation of the safety and efficacy of sertraline to treat depression in PD. A total of 15 patients with PD and depression participated in the study. Sertraline was introduced at a daily dose of 25 mg for 1 week and then increased to 50 mg/day. Patients underwent evaluation at baseline and at a final visit approximately 7 weeks later. Sertraline was generally well tolerated, but five patients experienced side effects, and two discontinued medication. Patients taking selegiline experienced more adverse effects. Beck Depression Inventory scores improved significantly (mean +/- SE = 16.0 +/- 2.0 vs 11.7 +/- 1.9, p = 0.03), and Unified Parkinson's Disease Rating Scale and energy-level scores were unchanged. These results suggest that sertraline may be a useful treatment for depression in PD. As substantial placebo effects can occur in studies of PD and depression, placebo-controlled, double-blind studies are warranted.

Authors+Show Affiliations

Department of Neurology, University of South Florida, Tampa, USA.No affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

9380061

Citation

Hauser, R A., and T A. Zesiewicz. "Sertraline for the Treatment of Depression in Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 12, no. 5, 1997, pp. 756-9.
Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord. 1997;12(5):756-9.
Hauser, R. A., & Zesiewicz, T. A. (1997). Sertraline for the treatment of depression in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 12(5), 756-9.
Hauser RA, Zesiewicz TA. Sertraline for the Treatment of Depression in Parkinson's Disease. Mov Disord. 1997;12(5):756-9. PubMed PMID: 9380061.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sertraline for the treatment of depression in Parkinson's disease. AU - Hauser,R A, AU - Zesiewicz,T A, PY - 1997/9/26/pubmed PY - 1997/9/26/medline PY - 1997/9/26/entrez SP - 756 EP - 9 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 12 IS - 5 N2 - Although antidepressant medications are commonly used to treat depression in Parkinson's disease (PD), little information is available regarding their safety and efficacy in this condition. Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inhibitor activity. It has a favorable tolerability profile, especially in the elderly. We undertook an open-label pilot evaluation of the safety and efficacy of sertraline to treat depression in PD. A total of 15 patients with PD and depression participated in the study. Sertraline was introduced at a daily dose of 25 mg for 1 week and then increased to 50 mg/day. Patients underwent evaluation at baseline and at a final visit approximately 7 weeks later. Sertraline was generally well tolerated, but five patients experienced side effects, and two discontinued medication. Patients taking selegiline experienced more adverse effects. Beck Depression Inventory scores improved significantly (mean +/- SE = 16.0 +/- 2.0 vs 11.7 +/- 1.9, p = 0.03), and Unified Parkinson's Disease Rating Scale and energy-level scores were unchanged. These results suggest that sertraline may be a useful treatment for depression in PD. As substantial placebo effects can occur in studies of PD and depression, placebo-controlled, double-blind studies are warranted. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/9380061/Sertraline_for_the_treatment_of_depression_in_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.870120522 DB - PRIME DP - Unbound Medicine ER -